What is Dekk-tec?
Established in 1983, Dekk-tec operates at the intersection of pharmaceutical innovation and medical device engineering. The company focuses on the development of advanced therapeutic agents, most notably DM-CHOC-PEN and various hydroperoxy analogs, which are engineered to manage both cancer and pre-cancerous lesions. By targeting high-acuity oncology markets, Dekk-tec has carved out a niche in the biotechnology sector, leveraging decades of experience in clinical development and regulatory navigation. Their business model, which includes the strategic licensing of intellectual property to larger biotech entities, demonstrates a sustainable approach to commercializing complex medical breakthroughs while maintaining a lean operational structure.
How much funding has Dekk-tec raised?
Dekk-tec has raised a total of $13K across 1 funding round:
Debt
$13K
Debt (2021): $13K with participation from PPP
Key Investors in Dekk-tec
PPP
Public-Private Partnership
What's next for Dekk-tec?
With the recent influx of capital, Dekk-tec is positioned to advance its lead therapeutic candidates through critical clinical trial phases. The strategic roadmap for the company involves intensifying its focus on regulatory submissions and expanding the clinical utility of its existing drug portfolio. As the firm transitions through its current growth stage, the primary objective remains the validation of its therapeutic agents in human trials, which will be instrumental in securing future licensing agreements or potential acquisition interest. By prioritizing the development of treatments for metastatic solid tumors, Dekk-tec aims to address significant unmet needs in the oncology landscape, ultimately enhancing patient outcomes while driving long-term value for its stakeholders.
See full Dekk-tec company page
